Newswise — The US Food and Drug Administration has approved Moderna’s mRNA vaccine for older adults to protect against respiratory syncytial virus (RSV). 

The vaccine, called mRESVIA, is for people ages 60 and older. 

According to a company press release, this marks the second approved mRNA product from Moderna and is the only pre-filled syringe available.

This approval is also the first time an mRNA vaccine has been approved for a disease other than COVID-19. 

George Washington University has experts available who can offer insight and analysis. If you would like to schedule an interview, please contact Katelyn Deckelbaum, [email protected].

Amanda Castel, is a professor of epidemiology at the GW Milken Institute School of Public Health and an expert in infectious diseases. She has served as an Epidemic Intelligence Service officer for the U.S. Centers for Disease Control and Prevention, spent over a decade working with local and state health departments and is board certified in pediatrics and preventive medicine and public health.

Michael Knight, is an assistant professor of medicine at GW School of Medicine and Health Sciences. He can discuss respiratory infections including RSV.

Maria Elena Ruiz is an associate professor of medicine and an infectious disease expert at the GW School of Medicine and Health Sciences. She can discuss RSV transmission and protection.

Emily R. Smith, is an assistant professor of global health at the GW Milken Institute School of Public Health. She is an epidemiologist who can discuss RSV and the approved vaccine.

Adriana Glenn is an assistant professor in the GW School of Nursing. She can discuss RSV, its symptoms and analysis of the new approved vaccine.